Hydroxamic acids as histone deacetylase inhibitors

Florian Thaler, Vaishali M. Patil, Satya P. Gupta

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

HDAC inhibition has been, for over a decade (and continues to remain), a highly competitive area. Hydroxamic acids represent the largest class of HDAC inhibitors. One product, SAHA is already approved and more than ten different chemical entities are in various clinical stages. A detailed discussion about compounds from various classes like phenyloxopropenyl, amidopropenyl analogues, spiropiperidines, biphenyl/arylamide/styrenyl, tetrahydroisoquinoline-based hydroxamic acid derivatives and N-hydroxyphenylacrylamide derivatives has been included along with the computational studies. It also covers brief details about the HDAC imaging agents. These successes as well as the enormous amount of experiences gained in preclinical and clinical studies may be useful-beyond the HDAC field-to future drug discovery programmes studying hydroxamic acid derivatives.

Original languageEnglish
Title of host publicationHydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities
PublisherSpringer-Verlag Berlin Heidelberg
Pages99-151
Number of pages53
ISBN (Print)9783642381119, 3642381103, 9783642381102
DOIs
Publication statusPublished - Jul 1 2013

Fingerprint

Hydroxamic Acids
Histone Deacetylase Inhibitors
Derivatives
Tetrahydroisoquinolines
Imaging techniques

Keywords

  • Chromatin
  • HDAC inhibitors
  • Histone deacetylases
  • Isoform selectivity
  • Nucleosome
  • Oral bioavailability

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Thaler, F., Patil, V. M., & Gupta, S. P. (2013). Hydroxamic acids as histone deacetylase inhibitors. In Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities (pp. 99-151). Springer-Verlag Berlin Heidelberg. https://doi.org/10.1007/978-3-642-38111-9_5

Hydroxamic acids as histone deacetylase inhibitors. / Thaler, Florian; Patil, Vaishali M.; Gupta, Satya P.

Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities. Springer-Verlag Berlin Heidelberg, 2013. p. 99-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thaler, F, Patil, VM & Gupta, SP 2013, Hydroxamic acids as histone deacetylase inhibitors. in Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities. Springer-Verlag Berlin Heidelberg, pp. 99-151. https://doi.org/10.1007/978-3-642-38111-9_5
Thaler F, Patil VM, Gupta SP. Hydroxamic acids as histone deacetylase inhibitors. In Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities. Springer-Verlag Berlin Heidelberg. 2013. p. 99-151 https://doi.org/10.1007/978-3-642-38111-9_5
Thaler, Florian ; Patil, Vaishali M. ; Gupta, Satya P. / Hydroxamic acids as histone deacetylase inhibitors. Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities. Springer-Verlag Berlin Heidelberg, 2013. pp. 99-151
@inbook{8d0d7bf270fb4274aba0eb861c5a302b,
title = "Hydroxamic acids as histone deacetylase inhibitors",
abstract = "HDAC inhibition has been, for over a decade (and continues to remain), a highly competitive area. Hydroxamic acids represent the largest class of HDAC inhibitors. One product, SAHA is already approved and more than ten different chemical entities are in various clinical stages. A detailed discussion about compounds from various classes like phenyloxopropenyl, amidopropenyl analogues, spiropiperidines, biphenyl/arylamide/styrenyl, tetrahydroisoquinoline-based hydroxamic acid derivatives and N-hydroxyphenylacrylamide derivatives has been included along with the computational studies. It also covers brief details about the HDAC imaging agents. These successes as well as the enormous amount of experiences gained in preclinical and clinical studies may be useful-beyond the HDAC field-to future drug discovery programmes studying hydroxamic acid derivatives.",
keywords = "Chromatin, HDAC inhibitors, Histone deacetylases, Isoform selectivity, Nucleosome, Oral bioavailability",
author = "Florian Thaler and Patil, {Vaishali M.} and Gupta, {Satya P.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-3-642-38111-9_5",
language = "English",
isbn = "9783642381119",
pages = "99--151",
booktitle = "Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities",
publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - Hydroxamic acids as histone deacetylase inhibitors

AU - Thaler, Florian

AU - Patil, Vaishali M.

AU - Gupta, Satya P.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - HDAC inhibition has been, for over a decade (and continues to remain), a highly competitive area. Hydroxamic acids represent the largest class of HDAC inhibitors. One product, SAHA is already approved and more than ten different chemical entities are in various clinical stages. A detailed discussion about compounds from various classes like phenyloxopropenyl, amidopropenyl analogues, spiropiperidines, biphenyl/arylamide/styrenyl, tetrahydroisoquinoline-based hydroxamic acid derivatives and N-hydroxyphenylacrylamide derivatives has been included along with the computational studies. It also covers brief details about the HDAC imaging agents. These successes as well as the enormous amount of experiences gained in preclinical and clinical studies may be useful-beyond the HDAC field-to future drug discovery programmes studying hydroxamic acid derivatives.

AB - HDAC inhibition has been, for over a decade (and continues to remain), a highly competitive area. Hydroxamic acids represent the largest class of HDAC inhibitors. One product, SAHA is already approved and more than ten different chemical entities are in various clinical stages. A detailed discussion about compounds from various classes like phenyloxopropenyl, amidopropenyl analogues, spiropiperidines, biphenyl/arylamide/styrenyl, tetrahydroisoquinoline-based hydroxamic acid derivatives and N-hydroxyphenylacrylamide derivatives has been included along with the computational studies. It also covers brief details about the HDAC imaging agents. These successes as well as the enormous amount of experiences gained in preclinical and clinical studies may be useful-beyond the HDAC field-to future drug discovery programmes studying hydroxamic acid derivatives.

KW - Chromatin

KW - HDAC inhibitors

KW - Histone deacetylases

KW - Isoform selectivity

KW - Nucleosome

KW - Oral bioavailability

UR - http://www.scopus.com/inward/record.url?scp=84929864716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929864716&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-38111-9_5

DO - 10.1007/978-3-642-38111-9_5

M3 - Chapter

AN - SCOPUS:84929864716

SN - 9783642381119

SN - 3642381103

SN - 9783642381102

SP - 99

EP - 151

BT - Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities

PB - Springer-Verlag Berlin Heidelberg

ER -